Unique ID issued by UMIN | UMIN000007477 |
---|---|
Receipt number | R000008822 |
Scientific Title | Study on usefulness of sitagliptin in patients with type 2 diabetes |
Date of disclosure of the study information | 2012/03/09 |
Last modified on | 2014/09/09 09:25:08 |
Study on usefulness of sitagliptin in patients with type 2 diabetes
JUMP study (Januvia on renal biomarkers and blood pressure)
Study on usefulness of sitagliptin in patients with type 2 diabetes
JUMP study (Januvia on renal biomarkers and blood pressure)
Japan |
Patients with type 2 diabetes (nephropathy stage I-III)
Endocrinology and Metabolism | Nephrology |
Others
NO
A prospective study of a DDP-4 inhibitor Januvia will be conducted in Japanese patients with type 2 diabetes (diabetic nephropathy stage I-III) to evaluate the efficacy in controlling blood glucose, reducing blood pressure, and improving diabetic nephropathy as well as safety.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
Change and %change in HbA1c after 12 months from baseline
Changes and %changes in the following parameters during the observation period
Office blood pressure
Home blood pressure (In principle, 7 values collected at each visit should be used for evaluation).
Body weight
Urinary albumin/creatinine
eGFR
Novel biomarkers including urinary megalin
Exploratory analyses
At the completion of the treatment period, stratified analyses based on background variables (status of monotherapy / combination therapy, age, and diabetic nephropathy stage, etc) will be conducted to evaluate the usefulness of Januvia in reducing blood glucose.
Moreover, its association with HbA1c, blood pressure, albuminuria, eGFR, and novel biomarkers will be analyzed.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Patients who fulfill the following criteria will be included in the study:
1) Patients who had received diet / exercise therapy alone or diet / exercise therapy and antidiabetic agents for more than 4 weeks, and whose blood glucose has not been sufficiently controlled (HbA1c 6.5% or fasting blood glucose 130mg/dL or casual blood glucose 180mg/dL).
2) Patients with diabetic nephropathy at stage I (pre-nephropathy) to stage III (overt proteinuria).
3) Patients for whom change of concomitant drugs including antihypertensives is considered not necessary in principle for at least 6 months
4) Outpatients aged20 years of both sexes who have given written informed consent on use of their data
Patients who meet any of the following criteria will be excluded from the study.
1) Patients with type 1 diabetes
2) Patients before or after operation, and those with severe infections or serious injury
3) Pregnant, possible pregnant, or lactating women
4) Patients with severe kidney dysfunction (serum creatinine2.5 mg/dL)
5) Patients with a history of hypersensitivity to Januvia
6) Patients who are considered not eligible for the study by the attending doctor due to medical reasons
200
1st name | |
Middle name | |
Last name | Akihiko Saito |
Niigata University Graduate School of Medical and Dental Sciences
Department of Applied Molecular Medicine
1-757 Asahimachi-dori, Chuo-ku, Niigata-shi
025-227-0915
akisaito@med.niigata-u.ac.jp
1st name | |
Middle name | |
Last name | Akihiko Saito |
Niigata University Graduate School of Medical and Dental Sciences
Department of Applied Molecular Medicine
1-757 Asahimachi-dori, Chuo-ku, Niigata-shi
025-227-0915
akisaito@med.niigata-u.ac.jp
Department of Applied Molecular Medicine, Niigata University Graduate School of Medical and Dental Sciences
Research foundation for community medicine
Non profit foundation
NO
新潟大学医歯学総合病院(新潟県)、新潟臨港病院(新潟県)、木戸病院(新潟県)、坂町病院(新潟県)、済生会三条病院(新潟県)、三条総合病院(新潟県)、小千谷総合病院(新潟県)、長岡赤十字病院(新潟県)、長岡中央綜合病院(新潟県)、六日町病院(新潟県)、小林医院(新潟県)、中新潟クリニック(新潟県)、鈴木内科小児科医院(新潟県)、村山内科(新潟県)、きくち内科医院(新潟県)、わかばやし内科クリニック(新潟県)、こばりファミリークリニック(新潟県)、えきまえクリニック内科はやし医院(新潟県)、林内科クリニック(新潟県)、岡田内科医院(新潟県)、いがらし内科医院(新潟県)、おおむら内科クリニック(新潟県)、押木内科神経内科医院(新潟県)、横田内科医院(新潟県)、笹川医院(新潟県)、小千谷総合病院附属十日町診療所(新潟県)
2012 | Year | 03 | Month | 09 | Day |
Unpublished
Completed
2010 | Year | 12 | Month | 20 | Day |
2011 | Year | 02 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2014 | Year | 01 | Month | 01 | Day |
2014 | Year | 02 | Month | 01 | Day |
2014 | Year | 03 | Month | 01 | Day |
A prospective study of a DDP-4 inhibitor Januvia will be conducted in Japanese patients with type 2 diabetes (diabetic nephropathy stage I-III) to evaluate the efficacy in controlling blood glucose, reducing blood pressure, and improving diabetic nephropathy as well as safety.
2012 | Year | 03 | Month | 09 | Day |
2014 | Year | 09 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008822
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |